Contineum Therapeutics, Inc. 10-Q

Item 5. Other Information. Trading Arrangements From time to time, our officers (as defined in Rule 16a - 1 (f) of the Exchange Act) and directors may enter into Rule 10b5 - 1 or non-Rule 10b5 - 1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended September 30, 2025 , none of our officers or directors adopted or terminated any such trading arrangements except as set forth below: Name Action Taken Type of Nature of Duration of Aggregate Number ( Title ) ( Date of Action ) Trading Arrangement Trading Arrangement Trading Arrangement of Securities Carmine Stengone ( President and Chief Executive Officer ) Adoption ( September 23, 2025 ) Rule 10b5 - 1 trading arrangement* Sale Until November 30, 2026 , or such earlier date upon which all transactions are completed or expire without execution Up to 231,925 shares Peter Slover ( Chief Financial Officer ) Adoption ( September 23, 2025 ) Rule 10b5 - 1 trading arrangement* Sale Until November 18, 2026 , or such earlier date upon which all transactions are completed or expire without execution Up to 41,730 shares Daniel Lorrain , Ph.D. ( Chief Scientific Officer ) Adoption ( September 23, 2025 ) Rule 10b5 - 1 trading arrangement* Sale Until November 30, 2026 , or such earlier date upon which all transactions are completed or expire without execution Up to 221,245 shares Timothy Watkins , M.D., M.Sc. ( Chief Medical Officer and Head of Development ) Adoption ( September 23, 2025 ) Rule 10b5 - 1 trading arrangement* Sale Until December 27, 2026 , or such earlier date upon which all transactions are completed or expire without execution Up to 173,333 shares * Intended to satisfy the affirmative defense of Rule 10b5 - 1 (c) 22 Table of Contents Item 6. Exhibits Exhibit Incorporated by Reference Filed Number Description Form File No. Exhibit Filing Date Herewith 3.1 Amended and Restated Certificate of Incorporation of the Registrant. 8-K 001-42001 3.1 04/09/2024 3.2 Amended and Restated Bylaws of the Registrant. 8-K 001-42001 3.2 04/09/2024 23 Table of Contents 31.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 31.2 Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 32.1* Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X 32.2* Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X 101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. X 101.SCH Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents. X 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). X _________________________________________ * The certifications furnished in Exhibit 32.1 and 32.2 hereto are deemed to be furnished with this Quarterly Report on Form 10-Q and will not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates them by reference. 24 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Contineum Therapeutics, Inc. October 30, 2025 By: /s/ Carmine Stengone Carmine Stengone President, Chief Executive Officer and Director (Principal Executive Officer) October 30, 2025 By: /s/ Peter Slover Peter Slover Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) 25